JP2012512165A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012512165A5 JP2012512165A5 JP2011540922A JP2011540922A JP2012512165A5 JP 2012512165 A5 JP2012512165 A5 JP 2012512165A5 JP 2011540922 A JP2011540922 A JP 2011540922A JP 2011540922 A JP2011540922 A JP 2011540922A JP 2012512165 A5 JP2012512165 A5 JP 2012512165A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- alkyl
- arylalkyl
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 125000003710 aryl alkyl group Chemical group 0.000 claims 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 11
- 125000000217 alkyl group Chemical group 0.000 claims 11
- -1 cycloheteroalkyl Chemical group 0.000 claims 11
- 239000001257 hydrogen Substances 0.000 claims 11
- 229910052739 hydrogen Inorganic materials 0.000 claims 11
- 125000003118 aryl group Chemical group 0.000 claims 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims 10
- 125000004404 heteroalkyl group Chemical group 0.000 claims 10
- 125000001072 heteroaryl group Chemical group 0.000 claims 10
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 201000006417 multiple sclerosis Diseases 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 125000001424 substituent group Chemical group 0.000 claims 6
- 125000004423 acyloxy group Chemical group 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- QKEBGAUJUHZNNU-UHFFFAOYSA-N 9h-pyrrolo[2,3-f]quinoxaline Chemical compound N1=CC=NC2=C(NC=C3)C3=CC=C21 QKEBGAUJUHZNNU-UHFFFAOYSA-N 0.000 claims 4
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 3
- 150000001408 amides Chemical class 0.000 claims 3
- 239000004202 carbamide Substances 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 125000001475 halogen functional group Chemical group 0.000 claims 3
- 229940002612 prodrug Drugs 0.000 claims 3
- 239000000651 prodrug Substances 0.000 claims 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 208000007118 chronic progressive multiple sclerosis Diseases 0.000 claims 2
- 229960002806 daclizumab Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 2
- 230000002519 immonomodulatory effect Effects 0.000 claims 2
- 239000003018 immunosuppressive agent Substances 0.000 claims 2
- 229940124589 immunosuppressive drug Drugs 0.000 claims 2
- 229960005027 natalizumab Drugs 0.000 claims 2
- 229960004641 rituximab Drugs 0.000 claims 2
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 claims 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
- 108010036949 Cyclosporine Proteins 0.000 claims 1
- 239000012848 Dextrorphan Substances 0.000 claims 1
- 108010072051 Glatiramer Acetate Proteins 0.000 claims 1
- 108010005716 Interferon beta-1a Proteins 0.000 claims 1
- 108010005714 Interferon beta-1b Proteins 0.000 claims 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 claims 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims 1
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 claims 1
- 229940099433 NMDA receptor antagonist Drugs 0.000 claims 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims 1
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 claims 1
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 claims 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- VOXIUXZAOFEFBL-UHFFFAOYSA-N Voacangin Natural products CCC1CC2CN3CC1C(C2)(OC(=O)C)c4[nH]c5ccc(OC)cc5c4C3 VOXIUXZAOFEFBL-UHFFFAOYSA-N 0.000 claims 1
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 claims 1
- 229960000548 alemtuzumab Drugs 0.000 claims 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims 1
- 229960003805 amantadine Drugs 0.000 claims 1
- 229960005370 atorvastatin Drugs 0.000 claims 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims 1
- 229960002170 azathioprine Drugs 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 229960005110 cerivastatin Drugs 0.000 claims 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 claims 1
- 229960001265 ciclosporin Drugs 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 229930182912 cyclosporin Natural products 0.000 claims 1
- 229960001985 dextromethorphan Drugs 0.000 claims 1
- JAQUASYNZVUNQP-PVAVHDDUSA-N dextrorphan Chemical compound C1C2=CC=C(O)C=C2[C@@]23CCN(C)[C@@H]1[C@H]2CCCC3 JAQUASYNZVUNQP-PVAVHDDUSA-N 0.000 claims 1
- 229950006878 dextrorphan Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960000556 fingolimod Drugs 0.000 claims 1
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 claims 1
- 229960003765 fluvastatin Drugs 0.000 claims 1
- 229960003776 glatiramer acetate Drugs 0.000 claims 1
- HSIBGVUMFOSJPD-CFDPKNGZSA-N ibogaine Chemical compound N1([C@@H]2[C@H]3C[C@H](C1)C[C@@H]2CC)CCC1=C3NC2=CC=C(OC)C=C12 HSIBGVUMFOSJPD-CFDPKNGZSA-N 0.000 claims 1
- OLOCMRXSJQJJPL-UHFFFAOYSA-N ibogaine Natural products CCC1CC2CC3C1N(C2)C=Cc4c3[nH]c5ccc(OC)cc45 OLOCMRXSJQJJPL-UHFFFAOYSA-N 0.000 claims 1
- AREITJMUSRHSBK-UHFFFAOYSA-N ibogamine Natural products CCC1CC2C3CC1CN2CCc4c3[nH]c5ccccc45 AREITJMUSRHSBK-UHFFFAOYSA-N 0.000 claims 1
- 229960004461 interferon beta-1a Drugs 0.000 claims 1
- 229960003161 interferon beta-1b Drugs 0.000 claims 1
- 229960003299 ketamine Drugs 0.000 claims 1
- 229960004577 laquinimod Drugs 0.000 claims 1
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 claims 1
- JNODQFNWMXFMEV-UHFFFAOYSA-N latrepirdine Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CCC1=CC=C(C)N=C1 JNODQFNWMXFMEV-UHFFFAOYSA-N 0.000 claims 1
- 229960004844 lovastatin Drugs 0.000 claims 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 claims 1
- 229960004640 memantine Drugs 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 229960001156 mitoxantrone Drugs 0.000 claims 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims 1
- 229960004866 mycophenolate mofetil Drugs 0.000 claims 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 claims 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 claims 1
- IMSBVIZCOASBDU-UHFFFAOYSA-N n-(2-aminophenyl)-4-phenyldiazenylbenzamide Chemical compound NC1=CC=CC=C1NC(=O)C1=CC=C(N=NC=2C=CC=CC=2)C=C1 IMSBVIZCOASBDU-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 claims 1
- 229950010883 phencyclidine Drugs 0.000 claims 1
- 229960002965 pravastatin Drugs 0.000 claims 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims 1
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 229960004181 riluzole Drugs 0.000 claims 1
- 229960000672 rosuvastatin Drugs 0.000 claims 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims 1
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 claims 1
- 229960002855 simvastatin Drugs 0.000 claims 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 0 *N(C(CCC1)c2c1c1ccccc1[n]2I)N Chemical compound *N(C(CCC1)c2c1c1ccccc1[n]2I)N 0.000 description 3
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12157408P | 2008-12-11 | 2008-12-11 | |
| US61/121,574 | 2008-12-11 | ||
| US23323509P | 2009-08-12 | 2009-08-12 | |
| US61/233,235 | 2009-08-12 | ||
| PCT/US2009/067673 WO2010068867A1 (en) | 2008-12-11 | 2009-12-11 | Methods for treating multiple sclerosis using tetracyclic pyrazinoindoles |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012512165A JP2012512165A (ja) | 2012-05-31 |
| JP2012512165A5 true JP2012512165A5 (enExample) | 2013-01-31 |
Family
ID=42243090
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011540922A Pending JP2012512165A (ja) | 2008-12-11 | 2009-12-11 | 四環系ピラジノインドールを用いた多発性硬化症の治療方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20110268699A1 (enExample) |
| EP (1) | EP2375900B1 (enExample) |
| JP (1) | JP2012512165A (enExample) |
| CN (1) | CN102395275A (enExample) |
| AU (1) | AU2009324495B2 (enExample) |
| BR (1) | BRPI0922871A2 (enExample) |
| CA (1) | CA2747235C (enExample) |
| IL (1) | IL213476A0 (enExample) |
| WO (1) | WO2010068867A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2340254B8 (en) | 2008-09-15 | 2014-05-21 | Biovista, Inc. | Compositions and methods for treating epilepsy |
| JP5934102B2 (ja) | 2009-10-30 | 2016-06-15 | レトロトップ、 インコーポレイテッドＲｅｔｒｏｔｏｐｅ， Ｉｎｃ． | Ｐｕｆａ誘導体による酸化ストレス障害の緩和 |
| RU2436786C1 (ru) * | 2010-07-23 | 2011-12-20 | Александр Васильевич Иващенко | Замещенные индолы, противовирусный активный компонент, способ получения и применения |
| CA2834342C (en) | 2011-04-26 | 2021-08-31 | Retrotope, Inc. | Impaired energy processing disorders and mitochondrial deficiency |
| WO2012148926A2 (en) * | 2011-04-26 | 2012-11-01 | Retrotope, Inc. | Neurodegenerative disorders and muscle diseases implicating pufas |
| KR102110175B1 (ko) | 2011-04-26 | 2020-05-13 | 레트로토프 인코포레이티드 | Ｐｕｆａ 산화와 관련된 장애 |
| AU2012249921B2 (en) | 2011-04-26 | 2017-06-08 | Biojiva Llc | Oxidative retinal diseases |
| WO2013130422A1 (en) * | 2012-02-27 | 2013-09-06 | Biovista, Inc. | Compositions and methods for treating mitochondrial diseases |
| CA2900503A1 (en) * | 2013-02-15 | 2014-08-21 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with laquinimod |
| KR101521807B1 (ko) * | 2014-01-20 | 2015-05-20 | 한국전자통신연구원 | 데이터 전송 제어 장치 및 그 방법 |
| MX373227B (es) * | 2014-05-09 | 2020-04-21 | Tecnimede Sociedade Tecnico Medicinal S | Sales farmacéuticamente aceptables de enantiómeros de pirlindol para utilizarse en medicina. |
| EP3380452B1 (en) | 2015-11-23 | 2021-03-24 | Retrotope, Inc. | Site-specific isotopic labeling of 1, 4-diene systems |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| SMT202500136T1 (it) | 2016-08-31 | 2025-05-12 | Mapi Pharma Ltd | Sistemi a deposito comprendenti glatiramer acetato |
| US11167003B2 (en) | 2017-03-26 | 2021-11-09 | Mapi Pharma Ltd. | Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems |
| EP3520803A1 (en) * | 2018-01-31 | 2019-08-07 | Zarodex Therapeutics Limited | Novel uses |
| US11779910B2 (en) | 2020-02-21 | 2023-10-10 | Biojiva Llc | Processes for isotopic modification of polyunsaturated fatty acids and derivatives thereof |
| US12109194B2 (en) | 2021-02-05 | 2024-10-08 | Biojiva Llc | Synergistic combination therapy for treating ALS |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3959470A (en) * | 1972-11-28 | 1976-05-25 | Mikhail Davidovich Mashkovsky | Psychotropic medicinal preparation |
| US5300645A (en) * | 1993-04-14 | 1994-04-05 | Eli Lilly And Company | Tetrahydro-pyrido-indole |
| US5795909A (en) * | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
| WO2004098638A1 (ja) * | 2003-05-06 | 2004-11-18 | Ono Pharmaceutical Co., Ltd. | エフェクター細胞機能阻害剤 |
| RU2281085C2 (ru) * | 2004-05-25 | 2006-08-10 | Закрытое акционерное общество "Мастерлек" | Антидепрессивные лекарственные средства для парентерального применения на основе сульфонатных солей пирлиндола |
| EP1688161A1 (en) * | 2004-11-02 | 2006-08-09 | Switch Biotech Aktiengesellschaft | Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis |
| CA2617102A1 (en) * | 2005-07-28 | 2007-02-08 | Bristol-Myers Squibb Company | Substituted tetrahydro-1h-pyrido[4,3,b]indoles as serotonin receptor agonists and antagonists |
| CA2688327A1 (en) * | 2007-05-25 | 2008-12-04 | Medivation Neurology, Inc. | Methods and compositions for stimulating cells |
-
2009
- 2009-12-11 CN CN200980154585XA patent/CN102395275A/zh active Pending
- 2009-12-11 US US13/133,553 patent/US20110268699A1/en not_active Abandoned
- 2009-12-11 BR BRPI0922871A patent/BRPI0922871A2/pt not_active Application Discontinuation
- 2009-12-11 CA CA2747235A patent/CA2747235C/en active Active
- 2009-12-11 AU AU2009324495A patent/AU2009324495B2/en not_active Ceased
- 2009-12-11 JP JP2011540922A patent/JP2012512165A/ja active Pending
- 2009-12-11 EP EP09832613.5A patent/EP2375900B1/en not_active Not-in-force
- 2009-12-11 WO PCT/US2009/067673 patent/WO2010068867A1/en not_active Ceased
-
2011
- 2011-06-12 IL IL213476A patent/IL213476A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012512165A5 (enExample) | ||
| JP2012505257A5 (enExample) | ||
| JP2009504764A5 (enExample) | ||
| JP2011500725A5 (enExample) | ||
| JP2008508289A5 (enExample) | ||
| JP2008509166A5 (enExample) | ||
| JP2017528524A5 (enExample) | ||
| JP2008507538A5 (enExample) | ||
| JP2010077141A5 (enExample) | ||
| JP2007517807A5 (enExample) | ||
| JP2010513523A5 (enExample) | ||
| JP2011515482A5 (enExample) | ||
| JP2012515225A5 (enExample) | ||
| JP2005519083A5 (enExample) | ||
| TW200621249A (en) | Substituted amide beta secretase inhibitors | |
| JP2018502925A5 (enExample) | ||
| JP2014511893A5 (enExample) | ||
| JP2014532730A5 (ja) | オピオイド受容体の調節物質およびそれを含む薬学的組成物 | |
| RU2009135277A (ru) | Гетероциклические ингибиторы аспартильной протеазы | |
| JP2018528261A (ja) | グルタミン類似体のプロドラッグ | |
| JP2012510502A5 (enExample) | ||
| JP2011513410A5 (enExample) | ||
| JP2006525276A5 (enExample) | ||
| JP2020523388A5 (enExample) | ||
| JP2014530881A5 (enExample) |